Mark McMahon, Global Practice Leader and Head of Alternative Investment Services for Alvarez & Marsal Valuation Services spoke at a webinar EMPEA, the global industry association for private capital in emerging markets, on valuation issues during COVID-19.
Mark gave practical insights and approaches on quantifying uncertainty and qualitative considerations when valuing private equity investments, as well as the unique challenges and considerations that differentiate this effort for credit funds. He also spoke on the operational challenges the current environment poses to mid-sized funds, where middle and back-office strains can mount quickly without the assistance of best in class tools and technologies.
Other speakers included: Paul Cunningham, Chairman and Board Member for IPEV, and CFO for Helios Investment Partners, and Carolina Espinal, Managing Director at HarbourVest. The moderator was Cate Ambrose, Chief Executive of EMPEA. The webinar is available to EMPEA members by clicking here.
In this third extract, Mark McMahon responds to Cate Ambrose’s questions about the role of the back office and the kind of operational resources needed to support valuation.
Financing Saudi Arabia’s Data Center Build-Out
August 6, 2026
Discover financing strategies for Saudi Arabia's data center build-out, from bankability and project finance to capital structuring and debt advisory.
Section 232 Pharmaceutical Duties: UK Rate Cut to Zero, and the Origin and Section 301 Questions That Follow
August 5, 2026
Effective July 31, 2026, the additional Section 232 tariff on patented pharmaceuticals that are products of the United Kingdom was reduced from 10% to zero (heading 9903.04.63), implementing the U.S.–UK Pharmaceutical Pricing Arrangement. Because UK patented pharmaceuticals remain subject to Section 232 (at a 0% rate), they also fall within the Section 232 carve-out from the new Section 301 forced labor tariffs — so qualifying UK patented product should face no additional duty under either regime.
Enterprise Management Incentive Plans - Recent Changes and Common Pitfalls
August 5, 2026
Enterprise Management Incentive (EMI) option plans have been at the centre of UK employee incentivisation for many years and remain popular with privately owned, fast-growing companies.
Better Data, Better Exits: The New Playbook for Wealth and Insurance Platform Roll-Ups
August 5, 2026
There’s a new value creation imperative for private equity (PE) firms and corporates seeking to roll up financial technology (FinTech) and data platform acquisitions, especially in the extended higher interest rate environment. Many of the traditional value enhancement strategies still matter, but operational platforming—integrating tech, data, and systems—can be a defining competitive advantage in roll-ups.
